IP Library Granted Patent US 8,286,640
Granted Patent B2
US 8,286,640 · App. 12/955,405 · Granted Oct 16, 2012

Apparatus and method for adjustable fractional optical dermatological treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,286,640
App. No.
12/955,405
Granted
Oct 16, 2012
Kind
B2
Abstract

A fractional treatment system can be configured with a laser wavelength that is selected such that absorption of the laser wavelength within the tissue increases as the tissue is heated by the laser (e.g., 1390-1425 nm). Desirably, the laser wavelength is primarily absorbed within a treated region of skin by water and has a thermally adjusted absorption coefficient within the range of about 8 cm −1 to about 30 cm −1 . An adjustable mechanism can be used to adjust the beam shape, beam numerical aperture, beam focus depth, and/or beam size to affect the treatment depth and or the character of the resulting lesions. The system may be designed to be switchable between a treatment mode that is semi-ablative and a treatment mode that is not semi-ablative. Adjustment of these parameters can improve the efficiency and efficacy of treatment. Illustrative examples of adjustable mechanisms include a set of spacers of different lengths, a rotatable turret with lens elements of different focal distances, an optical zoom lens, and a mechanical adjustment apparatus for adjusting the spacing between two optical lens elements.

Claims (32)

1. A method for fractional dermatological treatment, the method comprising:

directing an optical beam emitted by a laser source toward a target region of skin to deliver a fractional treatment to the target region of skin; and

adjusting one or more parameters of the optical beam selected from the group consisting of a size of the optical beam at the skin surface, a focal depth of the optical beam below the skin surface, a numerical aperture of the optical beam as the optical beam enters the skin, and a beam cross-sectional shape at the skin surface in response to a preselected pulse energy for the optical beam,

wherein the laser source is configured to emit optical energy at a laser wavelength in a range of 1350 nm to 1430 nm for which the absorption in water changes with temperature and increases as the tissue is heated from 30° C. to 80° C.

2. The method of claim 1 wherein the fractional treatment is semi-ablative to the target region of skin.

3. The method of claim 1 wherein the fractional treatment is not semi-ablative to the target region of skin.

4. The method of claim 1 wherein said laser wavelength is in the range of about 1390 nm to about 1425 nm.

5. The method of claim 4 wherein the laser source comprises a laser diode or a Raman-shifted ytterbium-doped fiber laser.

6. The method of claim 1 wherein said laser wavelength is in the range of about 1400 nm to about 1420 nm.

7. The method of claim 1 wherein said laser wavelength is about 1410 nm.

8. The method of claim 1 wherein said laser wavelength is in the range of about 1380 nm to about 1420 nm.

9. The method of claim 1 wherein the adjustment of the one or more parameters of the optical beam switches between a semi-ablative treatment mode for the preselected pulse energy for the optical beam and a treatment mode that is not semi-ablative for the preselected pulse energy.

10. The method of claim 1 wherein adjusting one or more parameters of the optical beam comprises:

adjusting the optical spot size of the optical beam at the surface of the skin.

11. The method of claim 10 wherein the optical spot size is within the range of about 50 μm and and is measured to the 1/e 2 intensity level of the optical beam.

12. The method of claim 1 wherein adjusting one or more parameters of the optical beam comprises:

adjusting the focal depth of the optical beam below the surface of the skin.

13. The method of claim 1 wherein adjusting one or more parameters of the optical beam comprises:

adjusting the numerical aperture of the optical beam as the optical beam enters the surface of the skin.

14. The method of claim 1 wherein one or more parameters of the optical beam are adjusted using an adjustable lens group.

15. The method of claim 1 wherein one or more parameters of the optical beam are adjusted by exchanging interchangeable optical elements.

16. The method of claim 1 wherein the laser wavelength is selected with at least one of the characteristics in the group consisting of

a thermally adjusted absorption coefficient of water in the skin is within the range of about 8 cm −1 to about 30 cm −1 ;

a thermally adjusted absorption coefficient of water in the skin is within the range of about 12 cm −1 to about 27 cm −1 ;

a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is less than about 0.7 (cm nm) −1 at the laser wavelength;

a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is within the range of about 0.3 to about 0.7 (cm nm) −1 at the laser wavelength;

the absorption of the laser wavelength by water in the skin increases by at least 10% as the temperature of water is increased from 30° C. to 80° C.;

the absorption of the laser wavelength by water in the skin increases by about 10% to about 24% as the temperature of water is increased from 30° C. to 80° C.; and

the absorption of the laser wavelength by water in the skin increases by about 16% to about 24% as the temperature of water is increased from 30° C. to 80° C.

17. The method of claim 1 wherein the laser wavelength is selected such that a thermally adjusted absorption coefficient of water in the skin at the laser wavelength is within the range of about 8 cm −1 to about 30 cm −1 , a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is within the range of about 0.3 to about 0.7 (cm nm) −1 at the laser wavelength, and the absorption of the laser wavelength by water in the skin increases by about 10% to about 24% as the temperature of the water is increased from 30° C. to 80° C.

18. The method of claim 1 wherein the laser wavelength is selected such that a thermally adjusted absorption coefficient of water in the skin at the laser wavelength is within the range of about 12 cm −1 to about 27 cm −1 , a derivative of the absorption for water at 30° C. in the skin with respect to wavelength is within the range of about 0.3 to about 0.7 (cm nm) −1 at the laser wavelength, and the absorption of the laser wavelength by water in the skin increases by about 16% to about 24% as the temperature of the water is increased from 30° C. to 80° C.

19. The method of claim 1 wherein the absorption of the laser wavelength by water in the skin increases by about 23% to about 26% as the temperature of water is increased from 30° C. to 80° C.

Assignments (13)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
Reel/Frame 073654/0300 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 071564/0463 →
U.S. PATENT SECURITY AGREEMENT Recorded Jun 13, 2025
From: MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; BAUSCH HEALTH US, LLC (F/K/A VALEANT PHARMACEUTICALS NORTH AMERICA LLC); PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; BAUSCH HEALTH AMERICAS, INC.; SOLTA MEDICAL, INC.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 071566/0200 →
SECURITY AGREEMENT (SECOND LIEN) Recorded Oct 5, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061606/0468 →
SECURITY AGREEMENT (FIRST LIEN) Recorded Oct 4, 2022
From: BAUSCH HEALTH US, LLC; BAUSCH HEALTH AMERICAS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 061595/0066 →
SECURITY INTEREST Recorded Jun 13, 2022
From: BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH, CANADA INC.; BAUSCH HEALTH IRELAND LIMITED; SOLTA MEDICAL IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 060346/0705 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
MERGER Recorded May 14, 2021
From: RELIANT TECHNOLOGIES, LLC
To: SOLTA MEDICAL, INC.
Reel/Frame 056244/0936 →
MERGER Recorded May 12, 2021
From: RELIANT TECHNOLOGIES, INC.
To: RELIANT TECHNOLOGIES, LLC
Reel/Frame 056218/0067 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →